GFA
CYTK icon

Gallagher Fiduciary Advisors’s Cytokinetics CYTK Stock Holding History

Gallagher Fiduciary Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$965K Sell
11,322
-255
-2% -$18.3K 0.03% 118
2026
Q1 		$763K Sell
11,577
-1,396
-11% -$88.7K 0.03% 107
2025
Q4 		$824K Buy
12,973
+1,182
+10% +$73.5K 0.03% 119
2025
Q3 		$648K Buy
+11,791
New +$486K 0.02% 120

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gallagher Fiduciary Advisors's CYTK Position: Q2 2026 in Review

Gallagher Fiduciary Advisors reduced its Cytokinetics (CYTK) stake by 2.2% in Q2 2026, selling an estimated $18.3K and leaving 11,322 shares worth $965K. The position accounts for 0.03% of the portfolio, ranked #118.

Gallagher Fiduciary Advisors first reported a position in CYTK in Q3 2025 and has held it in 4 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Gallagher Fiduciary Advisors held 11,322 shares of Cytokinetics worth $965K as of Q2 2026.
  • Gallagher Fiduciary Advisors sold 255 Cytokinetics shares in Q2 2026, an estimated $18.3K.
  • Cytokinetics made up 0.03% of Gallagher Fiduciary Advisors's portfolio in Q2 2026, its #118 holding.
  • Gallagher Fiduciary Advisors first reported a position in Cytokinetics in Q3 2025 and has held it in 4 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Gallagher Fiduciary Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.